mFOLFOXIRI

Org: Azienda Ospedaliera Universitaria Pisana, Veneto Institute of Oncology - IRCCS, San Bortolo General Hospital, CRO Aviano, Fondazione Poliambulanza,

Clinical trial

A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma

Status: Terminated, Estimated PCD: 2014-12-01

Abstract

Adjuvant chemotherapy with mFOLFOXIRI versus mFOLFOX6 in MRD-positive stage II-III colorectal cancer.

Org: Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, SYSU, Guangzhou, China, The Sixth Affiliated hospital, Sun Yat-sen University, Guangzhou, China, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Third Affiliated Hospital of Kunming Medical University, Kunming, China, Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,

Clinical trial

A Phase I/II Safety Lead in Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Irinotecan, Temozolomide, and Dinutuximab in Patients With Relapsed or Refractory Neuroblastoma: The Allo - STING Trial

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

Status: Completed, Estimated PCD: 2019-04-01

Clinical trial

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

A Pilot Study of Zimberelimab and Quemliclustat Combination With Chemotherapy in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Status: , Estimated PCD: 2025-05-01

Clinical trial

Paediatric Hepatic International Tumour Trial

Status: Active (not recruiting), Estimated PCD: 2026-08-01

Clinical trial

Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Status: Not yet recruiting, Estimated PCD: 2028-12-01

Clinical trial

Phase I/II Study of the Combination of Irinotecan and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) and Tislelizumab

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

Status: Completed, Estimated PCD: 2023-04-14

Clinical trial

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio- Marker-driven Cetuximab-based Treatment Regimen Over 3 Treatment Lines in mCRC Patients With RAS/BRAF wt Tumors at Start of First Line

Status: Active (not recruiting), Estimated PCD: 2025-08-15

Clinical trial

A Phase IIa (Pilot) Study of Neoadjuvant Chemotherapy With Folinic Acid, 5-FU, Irinotecan and Oxaliplatin (FOLFIRINOX) With Digoxin in Patients With Resectable Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2025-02-01

Clinical trial

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Status: Active (not recruiting), Estimated PCD: 2025-01-01

Clinical trial

Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 Alone in Locally Advanced Colorectal Cancer: a Randomized Control Phase II Study (OPTICAL-2)

Status: Recruiting, Estimated PCD: 2024-12-15

Clinical trial

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

A Real-world Observational Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients With Advanced Colorectal Cancer

Status: Recruiting, Estimated PCD: 2025-04-01

Clinical trial

Biomarker-oriented Study of Pembrolizumab in Combination With Chemotherapy in Chemotherapy -naïve Advanced Pancreatic Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Prospective Evaluation of the Effect of Curcumin on Dose-limiting Toxicity and Pharmacokinetics of Irinotecan in Colorectal Cancer Patients

Status: Completed, Estimated PCD: 2016-10-05

Clinical trial

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX in Patients With Initially Unresectable Colorectal Liver Metastasis

Status: Active (not recruiting), Estimated PCD: 2022-12-30

Clinical trial

A Randomized, Uncontrolled, Exploratory Phase 2 Trial of Irinotecan Plus Anlotinib or Further in Combination With Penpulimab as Second-line Treatment of Metastatic Colorectal Cancer (ZL-IRIAN)

Status: Recruiting, Estimated PCD: 2024-03-31

Clinical trial

FOLFOX Via Hepatic Artery Infusion Chemotherapy (HAI) Plus Systemic Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A Prospective, Randomized, Controlled Clinical Study

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Phase 2 Study of Neoadjuvant NIS793 in Combination With mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PDAC)

Status: Terminated, Estimated PCD: 2023-08-16

Clinical trial

The Efficacy and Safety of Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer: A Prospective, Single Arm, Phase II Clinical Study

Status: Not yet recruiting, Estimated PCD: 2026-01-01

Clinical trial

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Status: Recruiting, Estimated PCD: 2030-06-01

Clinical trial

A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer

Status: Completed, Estimated PCD: 2022-10-03

Clinical trial

Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2028-11-08

Clinical trial

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors: An Open-label, Phase II, Single-arm, Multi-center Trial

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy

Status: Completed, Estimated PCD: 2018-12-31

Clinical trial

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

Status: , Estimated PCD: 2026-04-01

Clinical trial

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2027-11-01

Clinical trial

Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab for Patients With Unresectable Colorectal Peritoneal Metastases

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS015 Combination Therapy in Patients With Advanced Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2025-11-30

Clinical trial

The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

Nordic Multicentre Un-blinded Phase II Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected

Status: Active (not recruiting), Estimated PCD: 2022-12-22

Clinical trial

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Status: Recruiting, Estimated PCD: 2024-04-01

Clinical trial

FUDR/Oxaliplatin HAI Plus Irinotecan Chemotherapy vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM

Status: Terminated, Estimated PCD: 2022-10-31

Clinical trial

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Status: Recruiting, Estimated PCD: 2025-12-01

Abstract

Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.

Org: University Hospital of Regensburg, University Medicine Greifswald, Pediatric Hematology and Oncology, University Medical Center Dresden, University of Jena, University Children's Hospital,

Abstract

Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).

Org: Institute of Clinical Medicine, University of Oslo, Institute of Clinical Sciences, Department of Surgery, The Sahlgrenska Academy, University of Gothenburg, Department of Biomedical and Clinical Sciences, Linköping University, Clatterbridge Cancer Centre NHS FT, School of Health Sciences, University of Skövde,

Abstract

Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.

Org: Novartis Pharma AG, F. Hoffmann-La Roche Ltd, Exelixis, Inc., VBL Therapeutics, Dana-Farber Cancer Institute,

Abstract

Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset.

Org: Baylor College of Medicine, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, MD Anderson Cancer Center Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.

Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,

Abstract

Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC).

Org: Abramson Cancer Center at the University of Pennsylvania, University of Pennsylvania, Department of Biostatistics, Epidemiology, and Informatics,

Abstract

A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China,

Abstract

The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC)—ISRCTN83842641.

Org: University of Leeds, University of Glasgow, University of Birmingham, Patient representative, Christie NHS Foundation Trust, Manchester, United Kingdom,

Abstract

A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer.

Org: Vanderbilt University Medical Center, Hunstman Cancer Hospital, University of Utah Health, University of Utah, University of California Irvine, University of Pittsburgh Medical Center (UPMC),

Abstract

Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type homologous recombination genes.

Org: Mayo Clinic Arizona, Phoenix, AZ, Caris Life Sciences, Irving, TX, Mayo Clinic, Department of Medicine, Duke University Medical Center, Caris MPI,

Abstract

Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).

Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,

Abstract

MicroOrganoSpheres as a clinically applicable precision oncology platform for the discovery of novel therapies in colorectal cancer.

Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Medical Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center,

Abstract

Development and evaluation of 5FUCore, OxaliCore, and IrinoCore transcriptomic signatures for predicting response to individual drugs in the FOLFIRINOX regimen: Towards toxicity reduction and personalized chemotherapy in PDAC.

Org: Cancer Research Center of Marseille (CRCM), Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, CNRS UMR 5309-INSERM U1209, Institut Paoli-Calmettes, Marseille, France, Aix-Marseille University CHU Timone,

Abstract

Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.

Org: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, Medical Oncology 1, Department of Oncology, Veneto Institute of Oncology IOV–IRCCS, Padova, Italy, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy,

Abstract

A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.

Org: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medical Oncology, Kochi Medical School, Nankoku-City, Japan, National Cancer Center Hospital East, Japan, Kashiwa-Shi, Japan, Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan, Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan,

Abstract

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.

Org: University of Florida/UF Health Cancer Center, University of Florida Health Cancer Center, Orlando Health Cancer Institute, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics,

Abstract

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.

Org: Renmin Hospital of Wuhan University, Xiantao First People’s Hospital, Jianghan Oilfield General Hospital, The Central Hospital of Xiao Gan, Xiang Yang Central Hospital,

Abstract

Efficacy and safety of irinotecan-eluting HepaSphere transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable colorectal liver metastases.

Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute,

Abstract

Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.

Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,

Abstract

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Org: University of Texas MD Anderson Cancer Center, The University of Pittsburgh, NRG Oncology SDMC, NSABP Foundation, Inc., UMPC Hillman Cancer Center,

Abstract

Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.

Org: mProbe Inc., Stanford University School of Medicine,

Abstract

HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.

Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,

Abstract

Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).

Org: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, New Brunswick, Roswell Park Comprehensive Cancer Center, Buffalo, IL, H. Lee Moffitt Cancer Center and Research Institute,

Abstract

SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES).

Org: Children's Hospital of Philadelphia, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Pediatric Oncology Branch, Clinical Center National Institutes of Health, Clinical Center National Institutes of Health, NIH / NCI,

Abstract

VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.

Org: Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University; Department of General Surgery Depart.2 (Colorectal Gastrointestinal Surgery), West China Tianfu Hospital, Sichuan University, Chengdu, China, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, Zhongshan Hospital, Fudan University, Shanghai, China, Shanghai, China, Gracell Biotechnologies, Ltd., Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,

Abstract

Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study.

Org: Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Cliniques Universitaires Saint-Luc, Department of Gastroenterology, Division of Digestive Oncology, Centre Léon Bérard,

Abstract

A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study.

Org: Department of Medical Oncology, Kochi Medical School, Nankoku-City, Japan, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan, Division of Gastroenterological Medicine, Kochi Health Sciences Center, Kochi, Japan, Department of Digestive and General Surgery, Faculty of Medicine, University of the Ryukyus, Nakagami-Gun Nishihara-Cho, Japan,

Abstract

A phase II clinical trial of prior regimen rechallenge in third- or later-line treatment for patients with metastatic colorectal cancer.

Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shangai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,

Abstract

The impact of cancer prehabilitation on psychological outcomes and quality of life in patients with gastro-oesophageal cancer.

Org: Imperial College, London Regional Cancer Center, Imperial College Healthcare NHS Trust,

Abstract

A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.

Org: Eli Lilly and Company, Pediatric Oncology-Hematology Department, National Cancer Center Hospital East, Kashiwa, Japan, Hospital U i P La Fe, Peter MacCallum Cancer Centre, Melbourne, Australia,

Abstract

Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Center GF Leclerc, Georges-François Leclerc Cancer Center, Georges François Leclerc Cancer Center – UNICANCER, Dijon, France, William Morey Hospital,

Abstract

Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.

Org: Peking University People's Hospital, Beijing, China,

Abstract

Anticancer–drug-induced interstitial lung disease (DIILD): With great power comes great responsibility.

Org: Syneos Health, Morrisville, NC, NC Medical Research, Gurugram, Indiana University – Purdue University Indianapolis,

Abstract

Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06).

Org: Soonchunhyang University Bucheon Hospital, Pusan National University Yangsan Hospital, Ulsan University Hospital, College of Medicine, Chungbuk National University, Seoul St. Mary's Hospital,

Abstract

Adverse events in real-world patients covered by Medicare with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX.

Org: Milliman, Inc., Ipsen Biopharmaceuticals, Inc., George Washington University Hospital,

Abstract

The adjuvant oxaliplatin-irinotecan paradox.

Org: Alara Medical Group, University of Texas Medical Branch at Galveston, UTMB Health,

Abstract

A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2–negative advanced breast cancer.

Org: Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital), Wuxi No.2 People’s Hospital, Jiangnan University Affiliated Hospital,

Abstract

Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium, BB-12 and Lactobacillus rhamnosus, LGG in colorectal cancer patients: The Probio SK 006-Slovak Cooperative Oncology Group trial.

Org: 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia, Faculty of Medicine, Comenius University, Bratislava, Slovakia, St. Jacob Hospital, Bardejov, Slovakia, NOU, Bratislava, Slovakia, NsP Trencin, Bratislava, Slovakia, National Cancer Institute, Bratislava, Slovakia, Zdravspol Sro, Komárno, Slovakia, NsP Milosrdní bratia, Bratislava, Slovakia, Klinika Radioterapie a Onkologie, Kosice, Slovak Republic, Faculty Hospital Trnava, Trnava, Slovakia, Trebisov Hospital, Trebisov, Slovakia, Poko Poprad, SRO, Poprad, Slovakia, Univerzitna Memocnica Martin, Martin, Slovakia, American Society of Clinical Oncology, Bratislava, VA, Slovakia, Comenius University, Faculty of Medicine, Bratislava, Slovakia, Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Slovakia, National Cancer Inst, Comenius University, Bratislava, Slovakia, Department of Oncohematology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia,

Abstract

A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).

Org: Institut Gustave Roussy, Villejuif, France, Hospital Universitario 12 de Octubre, Madrid, Spain, Spain,

Abstract

Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).

Org: University of Minnesota Masonic Cancer Center, Minneapolis, MN, Riley Hospital for Children at Indiana University Health, The Warren Alpert Medical School of Brown University, David Geffen School of Medicine UCLA, Cohen Children's Medical Center,

Abstract

Real-world treatment patterns and total cost of care in Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX.

Org: Milliman, Inc., Ipsen Biopharmaceuticals, Inc., George Washington University Hospital,

Abstract

Safety and efficacy of trifluridine/tipiracil plus bevacizumab in RAS mutated patients with metastatic colorectal cancer.

Org: 2nd Department of Surgery Aretaieion Hospital National and Kapodistrian University of Athens Medical School, Athens, Greece, 2nd Department of Surgery Aretaieion Hospital, Athens, Greece, 2nd Department of Suregery Aretaieion Hospital, Athens, Greece, 2nd Department of Surgery, Areteion Hospital National and Kapodistrian University, Athens, Greece, 2nd Department of Surgery, Areteion Hospital National and Kapodistrian University of Athens, Athens, Greece,

Abstract

Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm, phase Ⅱ study.

Org: Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Hangzhou, Zhejiang, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Affiliated Hangzhou First People’s Hospital,

Abstract

Updated results of the phase 1 I-FLOAT trial: Safety and efficacy of combining genotype-guided irinotecan with 5FU, leucovorin, oxaliplatin and docetaxel (gFOLFOXIRITAX) in advanced upper GI cancers.

Org: University of Chicago Medical Center, Chicago, IL, University of Chicago, Department of Medicine, Icahn School of Medicine at Mount Sinai, Section of Hematology & Oncology, University of Illinois Chicago,

Abstract

Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.

Org: Genesis Research, Ipsen Biopharmaceuticals, Inc., Dan Duncan Comprehensive Cancer Center, Baylor College of Medicine,

Abstract

Adverse events in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.

Org: Dan Duncan Comprehensive Cancer Center, Baylor College of Medicine, Genesis Research, Ipsen Biopharmaceuticals, Inc.,

Abstract

Overall survival in patients with recurrent glioblastomas with combination chemotherapy and tumor treating fields (TTF).

Org: University of Texas Health Science Center at Houston, University of Texas Health Science Center at Houston, McGovern Medical School,

Abstract

A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.

Org: Virginia Cancer Specialists, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan,

Abstract

The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer.

Org: Amplia Therapeutics, Melbourne, Australia, Australian Catholic University, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia,

Abstract

Long-term survivors (LTSs) population of metastatic colorectal cancer (mCRC): A Northern Italian comprehensive cancer center experience.

Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, AUSL-IRCCS Reggio Emilia,

Abstract

Patterns of treatment switching and healthcare resource utilization differences among real-world Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX.

Org: Milliman, Inc., Ipsen Biopharmaceuticals, Inc., George Washington University Hospital,

Abstract

Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS): A multicenter single-arm phase II trial.

Org: Qilu Hospital of Shandong University, Jinan, China National Biotec Group, Linyi Cancer Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China,

Abstract

Predictors of resistance to trastuzumab deruxtecan (T-DXd) in esophagogastric adenocarcinoma (EGC).

Org: Weill Cornell Medical Center/New York Presbyterian, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering/Weill Cornell Medical College, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center,

Abstract

Survival outcomes of liposomal irinotecan in patients with advanced pancreatic adenocarcinoma previously treated with conventional irinotecan-based chemotherapy: A single-institution experience.

Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Baltimore, MD,

Abstract

The prognostic impact of NKA dynamics in first-line treatment of metastatic colorectal cancer.

Org: Department of Biochemistry & Immunology, Danish Colorectal Cancer Center South, Institute of Regional Health Research, University Hospital of Southern Denmark, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Product

Pamrevlumab + Gemcitabine + Nab-paclitaxel

Clinical trial

A Phase IB Study FOLFIRINOX and NIS793 in Patients With Pancreatic Cancer

Status: Terminated, Estimated PCD: 2023-07-10